Logo image of PIII

P3 HEALTH PARTNERS INC (PIII) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PIII - US7444132044 - Common Stock

5.71 USD
-0.16 (-2.73%)
Last: 11/21/2025, 8:00:01 PM
Fundamental Rating

1

Overall PIII gets a fundamental rating of 1 out of 10. We evaluated PIII against 101 industry peers in the Health Care Providers & Services industry. PIII may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PIII is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PIII has reported negative net income.
In the past year PIII has reported a negative cash flow from operations.
PIII had negative earnings in each of the past 5 years.
PIII had a negative operating cash flow in each of the past 5 years.
PIII Yearly Net Income VS EBIT VS OCF VS FCFPIII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -19.95%, PIII is not doing good in the industry: 79.21% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -328.33%, PIII is doing worse than 81.19% of the companies in the same industry.
Industry RankSector Rank
ROA -19.95%
ROE -328.33%
ROIC N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PIII Yearly ROA, ROE, ROICPIII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

PIII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PIII Yearly Profit, Operating, Gross MarginsPIII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

0

2. Health

2.1 Basic Checks

PIII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PIII has been increased compared to 1 year ago.
Compared to 5 years ago, PIII has more shares outstanding
The debt/assets ratio for PIII is higher compared to a year ago.
PIII Yearly Shares OutstandingPIII Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
PIII Yearly Total Debt VS Total AssetsPIII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.98, we must say that PIII is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.98, PIII is not doing good in the industry: 83.17% of the companies in the same industry are doing better.
A Debt/Equity ratio of 2.30 is on the high side and indicates that PIII has dependencies on debt financing.
With a Debt to Equity ratio value of 2.30, PIII is not doing good in the industry: 75.25% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.3
Debt/FCF N/A
Altman-Z -0.98
ROIC/WACCN/A
WACC10.22%
PIII Yearly LT Debt VS Equity VS FCFPIII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.31 indicates that PIII may have some problems paying its short term obligations.
PIII's Current ratio of 0.31 is on the low side compared to the rest of the industry. PIII is outperformed by 92.08% of its industry peers.
PIII has a Quick Ratio of 0.31. This is a bad value and indicates that PIII is not financially healthy enough and could expect problems in meeting its short term obligations.
PIII's Quick ratio of 0.31 is on the low side compared to the rest of the industry. PIII is outperformed by 91.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.31
PIII Yearly Current Assets VS Current LiabilitesPIII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

5

3. Growth

3.1 Past

The earnings per share for PIII have decreased by -9.68% in the last year.
PIII shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.48%.
PIII shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.38% yearly.
EPS 1Y (TTM)-9.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.31%
Revenue 1Y (TTM)18.48%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-4.66%

3.2 Future

The Earnings Per Share is expected to grow by 25.98% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 2.14% on average over the next years.
EPS Next Y49.92%
EPS Next 2Y32.13%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next Year-5.4%
Revenue Next 2Y2.22%
Revenue Next 3Y2.14%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PIII Yearly Revenue VS EstimatesPIII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
PIII Yearly EPS VS EstimatesPIII Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200 -250

1

4. Valuation

4.1 Price/Earnings Ratio

PIII reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PIII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PIII Price Earnings VS Forward Price EarningsPIII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PIII Per share dataPIII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100 150 200

4.3 Compensation for Growth

A more expensive valuation may be justified as PIII's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.13%
EPS Next 3Y25.98%

0

5. Dividend

5.1 Amount

PIII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

P3 HEALTH PARTNERS INC

NASDAQ:PIII (11/21/2025, 8:00:01 PM)

5.71

-0.16 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners10.61%
Inst Owner Change-7.11%
Ins Owners3.19%
Ins Owner Change0.01%
Market Cap41.05M
Revenue(TTM)1.50B
Net Income(TTM)-145.97M
Analysts78
Price Target13.26 (132.22%)
Short Float %1.53%
Short Ratio3.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.04%
Min EPS beat(2)-28.86%
Max EPS beat(2)30.94%
EPS beat(4)1
Avg EPS beat(4)-255.59%
Min EPS beat(4)-658.17%
Max EPS beat(4)30.94%
EPS beat(8)2
Avg EPS beat(8)-149.43%
EPS beat(12)5
Avg EPS beat(12)-99.66%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.63%
Max Revenue beat(2)2.11%
Revenue beat(4)1
Avg Revenue beat(4)-1.74%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)2.11%
Revenue beat(8)3
Avg Revenue beat(8)0.83%
Revenue beat(12)6
Avg Revenue beat(12)0.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.88%
PT rev (3m)-4.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-51.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-33.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-41.68
EYN/A
EPS(NY)-11.81
Fwd EYN/A
FCF(TTM)-18.07
FCFYN/A
OCF(TTM)-18.07
OCFYN/A
SpS203.31
BVpS6.18
TBVpS-68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.95%
ROE -328.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity 2.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.31
Altman-Z -0.98
F-Score4
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)1.55%
Cap/Depr(5y)81.99%
Cap/Sales(3y)0.12%
Cap/Sales(5y)0.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.31%
EPS Next Y49.92%
EPS Next 2Y32.13%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue 1Y (TTM)18.48%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-4.66%
Revenue Next Year-5.4%
Revenue Next 2Y2.22%
Revenue Next 3Y2.14%
Revenue Next 5YN/A
EBIT growth 1Y-78.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year71.49%
EBIT Next 3Y27.35%
EBIT Next 5YN/A
FCF growth 1Y-20.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.19%
OCF growth 3YN/A
OCF growth 5YN/A

P3 HEALTH PARTNERS INC / PIII FAQ

Can you provide the ChartMill fundamental rating for P3 HEALTH PARTNERS INC?

ChartMill assigns a fundamental rating of 1 / 10 to PIII.


Can you provide the valuation status for P3 HEALTH PARTNERS INC?

ChartMill assigns a valuation rating of 1 / 10 to P3 HEALTH PARTNERS INC (PIII). This can be considered as Overvalued.


What is the profitability of PIII stock?

P3 HEALTH PARTNERS INC (PIII) has a profitability rating of 0 / 10.


Can you provide the financial health for PIII stock?

The financial health rating of P3 HEALTH PARTNERS INC (PIII) is 0 / 10.